Navidea Biopharmaceuticals Stock One Year Return
Navidea Biopharmaceuticals fundamentals help investors to digest information that contributes to Navidea Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Navidea Pink Sheet. The fundamental analysis module provides a way to measure Navidea Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Navidea Biopharmaceutica pink sheet.
Navidea |
Navidea Biopharmaceuticals Company One Year Return Analysis
Navidea Biopharmaceutica's One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
CompetitionBased on the recorded statements, Navidea Biopharmaceuticals has an One Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
All Next | Launch Module |
Navidea Fundamentals
Return On Equity | -11.0 | ||||
Return On Asset | -1.22 | ||||
Current Valuation | 3.5 M | ||||
Shares Outstanding | 100.08 M | ||||
Shares Owned By Insiders | 35.43 % | ||||
Shares Owned By Institutions | 1.50 % | ||||
Number Of Shares Shorted | 2.69 M | ||||
Price To Earning | 0.53 X | ||||
Price To Book | 8.16 X | ||||
Price To Sales | 84.14 X | ||||
Revenue | 65.65 K | ||||
Gross Profit | (119.3 K) | ||||
EBITDA | (14.05 M) | ||||
Net Income | (15.18 M) | ||||
Cash And Equivalents | 328.01 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 2.43 M | ||||
Debt To Equity | 1.20 % | ||||
Current Ratio | 0.22 X | ||||
Book Value Per Share | (0.01) X | ||||
Cash Flow From Operations | (8.99 M) | ||||
Short Ratio | 0.52 X | ||||
Earnings Per Share | (0.39) X | ||||
Target Price | 5.0 | ||||
Number Of Employees | 11 | ||||
Beta | 1.5 | ||||
Market Capitalization | 8.04 M | ||||
Total Asset | 4.37 M | ||||
Retained Earnings | (388 M) | ||||
Working Capital | (6.74 M) | ||||
Current Asset | 12.58 M | ||||
Current Liabilities | 6.18 M | ||||
Net Asset | 4.37 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |